Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Clin Cancer Res ; 26(8): 1997-2010, 2020 04 15.
Article in English | MEDLINE | ID: mdl-31964786

ABSTRACT

PURPOSE: The molecular drivers of antitumor immunity in pancreatic ductal adenocarcinoma (PDAC) are poorly understood, posing a major obstacle for the identification of patients potentially amenable for immune-checkpoint blockade or other novel strategies. Here, we explore the association of chemokine expression with effector T-cell infiltration in PDAC. EXPERIMENTAL DESIGN: Discovery cohorts comprised 113 primary resected PDAC and 107 PDAC liver metastases. Validation cohorts comprised 182 PDAC from The Cancer Genome Atlas and 92 PDACs from the Australian International Cancer Genome Consortium. We explored associations between immune cell counts by immunohistochemistry, chemokine expression, and transcriptional hallmarks of antitumor immunity by RNA sequencing (RNA-seq), and mutational burden by whole-genome sequencing. RESULTS: Among all known human chemokines, a coregulated set of four (CCL4, CCL5, CXCL9, and CXCL10) was strongly associated with CD8+ T-cell infiltration (P < 0.001). Expression of this "4-chemokine signature" positively correlated with transcriptional metrics of T-cell activation (ZAP70, ITK, and IL2RB), cytolytic activity (GZMA and PRF1), and immunosuppression (PDL1, PD1, CTLA4, TIM3, TIGIT, LAG3, FASLG, and IDO1). Furthermore, the 4-chemokine signature marked tumors with increased T-cell activation scores (MHC I presentation, T-cell/APC costimulation) and elevated expression of innate immune sensing pathways involved in T-cell priming (STING and NLRP3 inflammasome pathways, BATF3-driven dendritic cells). Importantly, expression of this 4-chemokine signature was consistently indicative of a T-cell-inflamed phenotype across primary PDAC and PDAC liver metastases. CONCLUSIONS: A conserved 4-chemokine signature marks resectable and metastatic PDAC tumors with an active antitumor phenotype. This could have implications for the appropriate selection of PDAC patients in immunotherapy trials.


Subject(s)
Biomarkers, Tumor/genetics , CD8-Positive T-Lymphocytes/immunology , Chemokine CCL4/genetics , Chemokine CCL5/genetics , Chemokine CXCL10/genetics , Chemokine CXCL9/genetics , Liver Neoplasms/secondary , Pancreatic Neoplasms/pathology , Biomarkers, Tumor/immunology , Chemokine CCL4/immunology , Chemokine CCL5/immunology , Chemokine CXCL10/immunology , Chemokine CXCL9/immunology , Cohort Studies , Computational Biology/methods , Databases, Genetic/statistics & numerical data , Humans , Immune Checkpoint Proteins/genetics , Immunotherapy/methods , Liver Neoplasms/genetics , Liver Neoplasms/immunology , Mutation , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/immunology , RNA-Seq/methods
2.
PLoS One ; 8(3): e60540, 2013.
Article in English | MEDLINE | ID: mdl-23555990

ABSTRACT

Activated B-cell lymphoma (ABC), one of the three subtypes of Diffuse Large B-cell Lymphoma (DLBCL) has the worst survival rate after upfront chemotherapy and is characterized by constitutively activated NFκB. We therefore studied the role of NFκB In a cohort of clinical DLBCL samples and ABC cell lines. In our clinical tissue microarray cohort of DLBCL samples, p-IκBα was detected in 38.3% of ABC DLBCL and was an independent prognostic marker for poor survival. In vitro, we found that Thymoquinone (TQ), a natural compound isolated from Nigella sativa caused release of ROS in ABC cells. TQ-mediated release of ROS in turn inhibited NFκB activity by dephosphorylating IκBα and decreased translocation of p65 subunit of NFκB in the nuclear compartment in ABC cell lines. This led to inhibition of cell viability and induction of mitochondrial dependent apoptosis in ABC-DLBCL cell lines. Additionally, TQ treatment also caused up-regulation of death receptor 5 (DR5), however, up-regulation of DR5 did not play a role in TQ-induced apoptosis. Finally, combination of sub-optimal doses of TQ and TRAIL induced efficient apoptosis in ABC-DLBCL cell lines. These data show that p-IκBα can be used as a prognostic marker and target for therapy in this aggressive sub-type of DLBCL and TQ may play an important role in the management of DLBCL in the future.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Benzoquinones/pharmacology , I-kappa B Proteins/antagonists & inhibitors , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Apoptosis/drug effects , Cell Line, Tumor , Cohort Studies , Female , Humans , I-kappa B Proteins/metabolism , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , NF-KappaB Inhibitor alpha , Nigella sativa/chemistry , Phosphorylation/drug effects , Prognosis , Receptors, TNF-Related Apoptosis-Inducing Ligand/analysis , TNF-Related Apoptosis-Inducing Ligand/pharmacology , Up-Regulation/drug effects
3.
Int J Clin Exp Pathol ; 4(7): 637-43, 2011.
Article in English | MEDLINE | ID: mdl-22076163

ABSTRACT

Leptin is a multifunctional adipose-derived cytokines that play a critical role in bodyweight homeostasis and energy balance. Recently, leptin and leptin receptor dysreulation have been reported in variety of malignant cells including thyroid. Leptin modulates growth and proliferation of cancer cells via activation of various growth and survival signaling pathways including JAK/STAT, PI3-kinase/AKT and/or Map kinases. In this review, current understanding of leptin's role in the pathogenesis of thyroid cancer has been described.


Subject(s)
Leptin/metabolism , Receptors, Leptin/metabolism , Thyroid Neoplasms/metabolism , Humans , Signal Transduction , Thyroid Neoplasms/pathology
5.
J Pathol ; 222(2): 180-90, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20632385

ABSTRACT

The inhibitor of apoptosis protein (IAP) family member X-linked inhibitor of apoptosis protein (XIAP) is essential for cell survival in lymphoma. However, the role of XIAP overexpression in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated. Therefore, we analysed the expression of XIAP protein and its clinicopathological correlation in a large cohort of DLBCLs by immunohistochemistry in a tissue micro-array format. XIAP was found to be overexpressed in 55% of DLBCLs and significantly associated with poor clinical outcome (p = 0.0421). To further elucidate the role of XIAP in DLBCL and the inter-relationship with PI3-kinase/AKT signalling, we conducted several in vitro studies using a panel of DLBCL cell lines. We found that pharmacological inhibition of XIAP led to caspase-dependent apoptosis in DLBCL cells. We also detected an inter-relationship between XIAP expression and activated AKT in DLBCL cells that may explain cellular resistance to PI3-kinase/AKT inhibition-mediated apoptosis. Finally, this anti-apoptotic effect was overcome by simultaneous pharmacological inhibition of XIAP and PI3-kinase/AKT signalling leading to a more potent synergistically induced apoptosis. In summary, our data suggest that XIAP expression is a poor prognostic factor in DLBCL and the XIAP-AKT relationship should be explored further as a potential therapeutic target in DLBCL.


Subject(s)
Biomarkers, Tumor/metabolism , Lymphoma, Large B-Cell, Diffuse/metabolism , Proto-Oncogene Proteins c-akt/physiology , X-Linked Inhibitor of Apoptosis Protein/metabolism , Aged , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Benzoquinones/pharmacology , Caspases/metabolism , Cell Division/drug effects , Chromones/pharmacology , Drug Evaluation, Preclinical/methods , Drug Resistance, Neoplasm , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Female , Humans , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Morpholines/pharmacology , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/metabolism , Neoplasm Staging , Phosphoinositide-3 Kinase Inhibitors , Prognosis , Signal Transduction , Survival Analysis , Tumor Cells, Cultured , X-Linked Inhibitor of Apoptosis Protein/antagonists & inhibitors
6.
Carcinogenesis ; 30(11): 1832-40, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19520793

ABSTRACT

We investigated the role of leptin receptor (Ob-R) and its relationship with phosphatidylinositol 3-kinase (PI3K)/AKT activation in colorectal carcinomas (CRCs) tissues followed by in vitro studies using a panel of CRC cell lines. Obesity serves an important risk factor of several cancers including CRC that ranks as the second most common cancer in Saudi Arabia. High levels of adipokine leptin (Ob) and its Ob-R are seen in obesity and also in various carcinomas including CRC. We investigated the proliferative and antiapoptotic effect of Ob on human CRC cell lines Caco-2, HT-29 and SW-840 and the role of PI3K/AKT-signaling pathway in mediating these actions. Then the expression of Ob-R and its relationship with clinicopathological features was analyzed in 448 CRC, 229 normal colon mucosa and 24 colorectal adenomas using tissue microarray technology. Treatment with Ob resulted in increased proliferation of CRC cell lines and involved activation of PI3K/AKT-signaling pathway. Pretreatment with Ob-R small interfering RNA or PI3K inhibitor inhibited these responses. Ob-R was significantly overexpressed in primary CRC relative to adenomas and normal colonic mucosa. In primary CRC, Ob-R significantly correlated with Ob expression, early stage and well-differentiated tumors. Intriguingly, patient with Ob-R positive tumors showed significantly better overall survival (P = 0.0098). Ob plays a critical role in CRC carcinogenesis through PI3K/AKT pathway via Ob-R. Ob-R is a prognostic marker associated with better survival.


Subject(s)
Adenoma/metabolism , Colorectal Neoplasms/metabolism , Leptin/metabolism , Receptors, Leptin/biosynthesis , Adenoma/etiology , Adenoma/mortality , Adenoma/pathology , Apoptosis/drug effects , Biomarkers, Tumor , Cell Line, Tumor , Cell Proliferation/drug effects , Colorectal Neoplasms/etiology , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Gene Expression Regulation, Neoplastic , Humans , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Leptin/pharmacology , Male , Neoplasm Staging , Obesity/complications , Obesity/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Saudi Arabia , Signal Transduction/drug effects , Survival Analysis
7.
Saudi Med J ; 29(1): 75-80, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18176677

ABSTRACT

OBJECTIVE: To evaluate the overall incidence of microsatellite instability (MSI), hereditary non polyposis colorectal cancer, and tumor supressor gene (TP53) mutations in Saudi colorectal carcinomas. METHODS: We studied the MSI pathway in Saudi colorectal cancers (CRC) from 179 unselected patients using 2 methods: MSI by polymerase chain reaction, and immunohistochemistry detection of mutL homologs 1 and mutS homologs 2 proteins. The TP53 mutations were studied by sequencing exons 5, 6, 7, and 8. RESULTS: Of the 150 colorectal carcinomas analyzed for MSI, 16% of the tumors showed high level instability (MSI-H), 19.3% had low-level instability (MSI-L) and the remaining 64% tumors were stable. Survival of the MSI-H group was better as compared to the MSI-L or microsatellite stable group (p=0.0217). In the MSI-H group, 48% were familial MSI tumors, which could be attributable to the high incidence of consanguinity in the Saudi population. The TP53 mutations were found in 24% of the cases studied. CONCLUSION: A high proportion of familial MSI cases and a lower incidence of TP53 mutations are some of the hallmarks of the Saudi colorectal carcinomas, which need to be explored further.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Genes, p53/genetics , Microsatellite Instability , Chi-Square Distribution , Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology , Colorectal Neoplasms, Hereditary Nonpolyposis/ethnology , Genetic Markers , Genetics, Population , Humans , Immunohistochemistry , Incidence , Microarray Analysis , Mutation , Pilot Projects , Polymerase Chain Reaction , Saudi Arabia/epidemiology
8.
Saudi Med J ; 27(3): 323-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16532091

ABSTRACT

OBJECTIVE: To document the incidence and role of p53 and DNA mismatch repair proteins in colorectal carcinomas, and to evaluate the relative frequency of major molecular pathways in colorectal cancers from Saudi Arabia. METHODS: We collected the formalin fixed, paraffin embedded tissues from 154 colorectal tumors (83 patients from King Faisal Specialist Hospital and Research Centre and 71 from Saudi Aramco Dhahran Health Centre) between January 1989 and December 2003. We analyzed the p53 and mismatch repair gene expression (hMSH-2, hMLH-1) by immunohistochemistry in tissue microarray format. RESULTS: Expression loss of at least one mismatch repair gene was found in 33.8% of cases and significantly associated with the right-sided tumor location (p=0.0047). The p53 positivity was observed in 57.5% of tumors, and was inversely linked to expression loss of mismatch repair genes (p=0.0102). CONCLUSION: The strong confirmation of the previously established associations between tumor phenotype, and mismatch repair gene alteration provided strong evidence for the validity of our experimental approach. Together with the higher incidence of right sided location in Saudi (46.6%) than in Western colon cancers (34.9%), the observed high prevalence of mismatch gene expression loss in Saudi tumors argues for a higher importance of microsatellite instability in this population. If confirmed, it will be interesting to see whether an increased level of familial or sporadic microsatellite instability cases is causing this variation.


Subject(s)
Carrier Proteins/genetics , Colorectal Neoplasms/genetics , Genes, p53 , MutS Homolog 2 Protein/genetics , Nuclear Proteins/genetics , Adaptor Proteins, Signal Transducing , Adult , Colorectal Neoplasms/epidemiology , Female , Humans , Immunohistochemistry , Incidence , Male , MutL Protein Homolog 1 , Oligonucleotide Array Sequence Analysis , Saudi Arabia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...